The drug was being assessed to treat acute postoperative pain in patients following bunionectomy surgery. In the phase III clinical trial, IV meloxicam achieved the primary endpoint of
Janssen will carry out a phase 2 trial, which will test the tolerability and clinical activity of its investigational immunotherapy JNJ-64041757 with BMS’ PD-1 immune checkpoint inhibitor, Opdivo
The US Food and Drug Administration (FDA) has granted V920 a breakthrough therapy designation which aims to expedite the development and review of a candidate that is planned
The Series C round, which brings Tricida’s total financing to $95M, was led by new investor Longitude Capital. New investor Vivo Capital and existing investors OrbiMed, Sibling Capital
The phase 1/2 clinical trial will evaluate the safety, tolerability, and efficacy of BMS’s Opdivo and Opdivo + Yervoy in conjunction with AbbVie’s Rova-T, a delta-like protein 3
Valeant has received a complete response letter (CRL) from the FDA for latanoprostene bunod (LBN) ophthalmic solution 0.024%, an intraocular pressure lowering single-agent eye drop for patients with
The once-daily Truvada (emtricitabine 200 mg/tenofovir disoproxil 245 mg) in combination with safer sex practices is intended to lower the risk of sexually acquired HIV-1 infection among uninfected
At the same time, the FDA has granted Fast Track designation to the compound’s development program for the treatment of CDI. MCB3837 is the IV prodrug of MCB3681,
New investors such as Staidson Hongkong Investment, international industrial investors and family offices as well as existing investors participated in the financing round. IFX-1 is a monoclonal anti-complement
The phase 3 study evaluated the effectiveness and safety of ABP 980 compared with trastuzumab in adult female patients with HER2-positive early breast cancer. There were 725 patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.